A Study of AAV2-GDNF in Adults with Moderate Parkinsons Disease (REGENERATE-PD)
Recruiting
99 years and younger
All
Phase
2
1 Location
Brief description of study
The study is designed to evaluate the efficacy and safety of intraputaminal delivery of AAV2-GDNF gene therapy in subjects with moderate Parkinson's disease and demonstrate proof-of-concept. Subjects will be randomized to 1 of 2 treatment arms, AAV2-GDNF surgery or control surgery and will undergo screening, two baseline visits, perioperative procedures, and double-blind follow-up. Procedures include biological fluid sampling; MRI, CT, PET imaging, clinical assessments; and activity monitoring.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855437
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
